Colon cancers with the KRAS mutation showed upregulated expression of CXCL3 and PD-L1 in cancer cells, decreased granzyme B levels in cancer tissues, and increased M2 macrophage numbers in the TIM (Supplementary Fig. 12e), supporting previous findings from a report of a model showing the characteristics of cancers with KRAS mutations [58]. This evidence concerns the gene CXCL3 and colonic neoplasm.